IFx-Hu2.0 not checked
TuHURA Biosciences, Inc. · pAc/emm55
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Therapeutic Classification: • Innate immune agonist Route of Administration: • Intralesional”In the company’s words, NCT06947928 on ClinicalTrials.gov
- Tested for
- Advanced Or Metastatic Merkel Cell Carcinoma (2 trials)
- Main trialPhase 2/3
- “This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via intralesional injection in a single lesion, followed by pembrolizumab.”In the company’s words, NCT06947928 on ClinicalTrials.gov
- Other names
- pAc/emm55
Other drugs for Advanced Or Metastatic Merkel Cell Carcinoma
- PembrolizumabMerck & Co. · Phase 3
- EIK1001Eikon Therapeutics · Phase 2/3
- QL2107Qilu Pharmaceutical · Phase 3
- FutibatinibTaiho · Phase 2/3
- MB11mAbxience Research S.L. · Phase 3
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
Coming up2
- 31 Mar 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Apr 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 31 Mar 2027 | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | |
| Phase 1Recruiting | Apr 2027 | IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | |
| Phase 1Completed | 7 Oct 2021 | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer | |
| Phase 1Completed | 19 Oct 2023 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026